By Nadya Masidlover
PARIS--French pharmaceutical company Sanofi SA (SNY) and
Regeneron Pharmaceuticals Inc. (REGN) said they will seek U.S.
regulatory approval for a new rheumatoid arthritis drug later this
year.
The two companies said Thursday that the results from phase 3
studies of Sarilumab were positive in treating the symptoms of
rheumatoid arthritis.
"Sarilumab is the first fully-human monoclonal antibody directed
against the IL-6 receptor (IL-6R). Sarilumab binds with high
affinity to the IL-6 receptor," the companies said.
They said that a request for U.S. regulatory approval will be
put forward in the fourth quarter of 2015.
-Write to Nadya Masidlover at nadya.masidlover@wsj.com
Access Investor Kit for Sanofi
Visit
http://www.companyspotlight.com/partner?cp_code=P479&isin=FR0000120578
Access Investor Kit for Regeneron Pharmaceuticals, Inc.
Visit
http://www.companyspotlight.com/partner?cp_code=P479&isin=US75886F1075
Access Investor Kit for Sanofi
Visit
http://www.companyspotlight.com/partner?cp_code=P479&isin=US80105N1054
Subscribe to WSJ: http://online.wsj.com?mod=djnwires